199 related articles for article (PubMed ID: 26519653)
1. Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Maurice MJ; Zhu H; Kiechle JE; Kim SP; Abouassaly R
J Urol; 2016 Apr; 195(4 Pt 1):919-24. PubMed ID: 26519653
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
J Urol; 2015 Aug; 194(2):343-9. PubMed ID: 25681290
[TBL] [Abstract][Full Text] [Related]
3. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
[TBL] [Abstract][Full Text] [Related]
4. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
5. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Berglund RK; Masterson TA; Vora KC; Eggener SE; Eastham JA; Guillonneau BD
J Urol; 2008 Nov; 180(5):1964-7; discussion 1967-8. PubMed ID: 18801515
[TBL] [Abstract][Full Text] [Related]
6. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
7. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
8. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
9. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
10. Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.
Jain S; Loblaw A; Vesprini D; Zhang L; Kattan MW; Mamedov A; Jethava V; Sethukavalan P; Yu C; Klotz L
J Urol; 2015 Jul; 194(1):79-84. PubMed ID: 25660208
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
12. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
13. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
[TBL] [Abstract][Full Text] [Related]
14. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
15. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
17. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer volume at biopsy predicts clinically significant upgrading.
Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
[TBL] [Abstract][Full Text] [Related]
19. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
[TBL] [Abstract][Full Text] [Related]
20. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
